Page 2: Health Product InfoWatch – February 2018

Key messages for healthcare professionals:^{Reference 1}

• Repeated use or abuse of this product may lead to corneal epithelial toxicity and defects, which may progress to permanent corneal damage, such as corneal opacification with accompanying loss of vision.
• Alcaine should only be put into patients' eyes by a healthcare professional and should not be dispensed for patients' own use.

Key messages for healthcare professionals:^{Reference 2}

• Cerebrovascular disorders (including cerebral vasculitis and cerebral hemorrhage) have been reported with the use of Concerta.
• Consider cerebrovascular disorders as a possible diagnosis in any patient who develops new neurological symptoms that are consistent with cerebral ischemia during Concerta therapy. These symptoms could include severe headache, unilateral weakness or paralysis, and impairment of coordination, vision, speech, language, or memory.
• If a cerebrovascular disorder is suspected during treatment, discontinue Concerta immediately.
• In patients with pre-existing cerebrovascular disorders (e.g., aneurysm, vascular malformations/anomalies), treatment with Concerta is not recommended.

Key messages for healthcare professionals:^{Reference 3}

• Sertraline has been demonstrated to cause a concentration-dependent prolongation of the QTc interval.
• Caution should be exercised when sertraline is prescribed in patients with an increased risk of QT prolongation including but not limited to those who are suspected to be at an increased risk of experiencing torsade de pointes during treatment with a QTc-prolonging drug.